MAGT1 is required for HeLa cell proliferation through regulating p21 expression, S-phase progress, and ERK/p38 MAPK MYC axis

Cell Cycle. 2021 Nov;20(21):2233-2247. doi: 10.1080/15384101.2021.1974792. Epub 2021 Sep 9.

Abstract

Magnesium transporter subtype 1 (MAGT1) is known to participate in animal development and cell differentiation. Thus far, MAGT1 studies have mainly focused on its role in cardiomyocyte regulation and differentiation; only a few studies have demonstrated its role in cell proliferation. To investigate the underlying mechanism of MAGT1 in cell proliferation, HeLa and SiHa cells were transiently knocked down with different siRNAs. We showed that cell proliferation was substantially restricted by S-phase arrest and apoptosis in the MAGT1-knocked down cells, which was further confirmed by the increased expression of p21, cyclin-A1, and cyclin-B1, as well as the decreased expression of MYC, cyclin-D1, cyclin-E1, and CDK2. MAGT1 knockdown also resulted in significant changes in the transcriptional expression of 1,598 genes that were analyzed by RNA sequencing. Bioinformatics analysis showed that MAGT1 was related to the MAPK signaling pathway. Western blot analysis confirmed that the phosphorylation of extracellular signal-related protein kinase 1/2 (ERK1/2) and p38 was remarkably reduced in MAGT1 down-regulated groups. Additionally, MAGT1 was required for the function of viral proteins E6/E7 during cell proliferation and G1/S cell-cycle progression. Therefore, MAGT1 plays a crucial role in the proliferation of HPV-positive cervical cancer cells, S-phase progression, and the ERK/p38 MAPK signaling pathway. These results indicate the potential of MAGT1 as a novel target for anticancer research.Abbreviations: MAGT1: Magnesium transporter subtype 1; MAPK: Mitogen-activated protein kinase; XMEN: X-linked immunodeficiency with Magnesium defect, Epstein-Barr virus infection and Neoplasia; BMMSCs: Bone Marrow Mesenchymal Stem Cells; Dpp: Decapentaplegic; CDKIs: CDK inhibitors; GPCR: G-protein coupled receptor; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; RTK: Receptor Tyrosine Kinase; PTK: Protein Tyrosine Kinase; FGFR: Fibroblast Growth Factor Receptor; BMP: Bone Morphogenetic Protein; HPV18 E6/E7: Human Papillomavirus 18 Early protein 6/ early protein 7; FACS: Fluorescence Activated Cell Sorting; PI: Propidium Iodide.

Keywords: MAGT1; MAPK; MYC; S-phase arrest; p21.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cation Transport Proteins*
  • Cell Proliferation
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Epstein-Barr Virus Infections*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • HeLa Cells
  • Herpesvirus 4, Human / metabolism
  • Humans
  • Proto-Oncogene Proteins c-myc
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Cation Transport Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • MYC protein, human
  • MagT1 protein, human
  • Proto-Oncogene Proteins c-myc
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases

Grants and funding

We gratefully acknowledge support from the National Natural Science Foundation of China [No. 81770018 and 82070020 to H.S.], The Natural Science Research of Jiangsu Higher Education Institutions of China (CN) [No. 20KJB310015 to C.B.], The Distinguished Doctoral Program of Green Yang Golden Phoenix of Yangzhou City [2018 to X.Z., and 2019 to C.B.], The Talent Introduction Fund of Yangzhou University [No. 137011476 to X.Z., and No. 137011478 to C.B.], The China Postdoctoral Science Foundation [No. 2020M671636 to X.Z., and No. 2019M651988 to W.L.], The Postdoctoral Science Foundation of Jiangsu Province (CN) [No. 2018K083B to W.L.], The Yangzhou Key Research and Development projects [No. YZ2020084 to W.L.], and The Yangzhou University students’ science and technology innovation project [No. X20200754 to W.L.], and The Natural Science Foundation of Anhui Provincial Education Bureau [No. KJ2016A433 to D.L.]. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.